Tempus AI says multi-center study validates FDA-cleared ECG model predicting 1-year atrial fibrillation risk

Tempus Al

Tempus Al

TEM

0.00
  • Tempus AI disclosed a Heart Rhythm publication validating its FDA-cleared ECG-AF software for predicting 12-month atrial fibrillation risk.
  • Results have already been presented via the peer-reviewed publication, not flagged for a future conference readout.
  • The multi-center study found the model met performance expectations across different clinical settings, supporting its use as a decision-support tool.
  • Management framed the product as a shift toward earlier detection to reduce downstream complications, strengthening its cardiovascular device portfolio.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempus AI Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202606110830BIZWIRE_USPR_____20260611_BW397471) on June 11, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.